1. Reply to: No correlation between estimated and actual glomerular filtration rates in pediatric oncology patients.

    Pediatric Blood & Cancer 62(7):1300 (2015) PMID 25777466

  2. Focal nodular hyperplasia in children: An institutional experience with review of the literature

    Journal of Pediatric Surgery 50(3):382 (2015)

    Background Focal nodular hyperplasia (FNH) is uncommonly diagnosed in pediatric patients and may be difficult to distinguish from a malignancy. We present a review of all children with a tissue diagnosis of FNH at our institution, describe the diagnostic modalities, and provi...
  3. Focal nodular hyperplasia in children: An institutional experience with review of the literature.

    Journal of Pediatric Surgery 50(3):382 (2015) PMID 25746693

    Focal nodular hyperplasia (FNH) is uncommonly diagnosed in pediatric patients and may be difficult to distinguish from a malignancy. We present a review of all children with a tissue diagnosis of FNH at our institution, describe the diagnostic modalities, and provide recommendations for diagnosi...
  4. Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging.

    Pediatric Radiology 44(10):1275 (2014) PMID 24839140

    Children with hepatoblastoma routinely undergo repetitive surveillance imaging, with CT scans for several years after therapy, increasing the risk of radiation-induced cancer. The purpose of this study was to determine the utility of surveillance CT scans compared to serum alpha-fetoprotein (AFP...
  5. Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging.

    Pediatric Radiology 44(10):1275 (2014) PMID 24839140

    Children with hepatoblastoma routinely undergo repetitive surveillance imaging, with CT scans for several years after therapy, increasing the risk of radiation-induced cancer. The purpose of this study was to determine the utility of surveillance CT scans compared to serum alpha-fetoprotein (AFP...
  6. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

    Clinical Cancer Research 19(23):6578 (2013) PMID 24097866 PMCID PMC4079262

    Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent specific inhibitor of telomerase. It binds with high affinity to the template region of the RNA component of human telomerase (hTERC) and is a competitive inhibitor of telomerase enzymatic activ...
  7. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

    Clinical Cancer Research 19(23):6578 (2013) PMID 24097866 PMCID PMC4079262

    Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent specific inhibitor of telomerase. It binds with high affinity to the template region of the RNA component of human telomerase (hTERC) and is a competitive inhibitor of telomerase enzymatic activ...
  8. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

    Clinical Cancer Research 19(23):6578 (2013) PMID 24097866 PMCID PMC4079262

    Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent specific inhibitor of telomerase. It binds with high affinity to the template region of the RNA component of human telomerase (hTERC) and is a competitive inhibitor of telomerase enzymatic activ...
  9. Extrarenal Wilms tumor: a case report and review of the literature.

    Journal of Pediatric Surgery 48(6):E33 (2013) PMID 23845655

    Extrarenal Wilms tumors are extremely rare with only isolated case reports in the pediatric literature. We present the case of a 2-year old boy who presented with a large abdominal mass and constipation. Pathologic diagnosis of the tumor was extrarenal Wilms tumor (ERWT) with favorable histology...
  10. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

    Neuro-Oncology 15(6):759 (2013) PMID 23592571 PMCID PMC3661085

    We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas. Child...
  11. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

    Neuro-Oncology 15(6):759 (2013) PMID 23592571 PMCID PMC3661085

    We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas. Child...
  12. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

    Neuro-Oncology 15(6):759 (2013) PMID 23592571 PMCID PMC3661085

    We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas. Child...
  13. Extrarenal Wilms tumor: a case report and review of the literature

    Journal of Pediatric Surgery 48(6):e33 (2013)

    Extrarenal Wilms tumors are extremely rare with only isolated case reports in the pediatric literature. We present the case of a 2-year old boy who presented with a large abdominal mass and constipation. Pathologic diagnosis of the tumor was extrarenal Wilms tumor (ERWT) with favorable...
  14. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

    Neuro-Oncology 15(6):759 (2013) PMID 23592571 PMCID PMC3661085

    We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas. Child...
  15. Unusually early presentation of small-bowel adenocarcinoma in a patient with Peutz-Jeghers syndrome.

    Journal of Pediatric Hematology/Oncology 35(4):323 (2013) PMID 23426006 PMCID PMC3708690

    Peutz-Jeghers syndrome (PJS) is an autosomal dominant cancer predisposition syndrome characterized by melanotic macules and hamartomatous polyps. Small-bowel surveillance in the pediatric PJS population is not designed to identify small-bowel malignancy, which is thought to arise in adulthood. A...
  16. Unusually early presentation of small-bowel adenocarcinoma in a patient with Peutz-Jeghers syndrome.

    Journal of Pediatric Hematology/Oncology 35(4):323 (2013) PMID 23426006 PMCID PMC3708690

    Peutz-Jeghers syndrome (PJS) is an autosomal dominant cancer predisposition syndrome characterized by melanotic macules and hamartomatous polyps. Small-bowel surveillance in the pediatric PJS population is not designed to identify small-bowel malignancy, which is thought to arise in adulthood. A...
  17. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

    Pediatric Blood & Cancer 60(3):390 (2013) PMID 22887890 PMCID PMC3511610

    A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m...
  18. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

    Pediatric Blood & Cancer 60(3):390 (2013) PMID 22887890 PMCID PMC3511610

    A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m...
  19. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

    Cancer Chemotherapy and Pharmacology 71(3):749 (2013) PMID 23314734

    The aim of the current investigation was to develop a population pharmacokinetic model for doxorubicin and doxorubicinol that could provide improved estimated values for the pharmacokinetic parameters clearance of doxorubicin, volume of distribution of the central compartment, clearance of doxor...
  20. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

    Cancer Chemotherapy and Pharmacology 71(3):749 (2013) PMID 23314734

    The aim of the current investigation was to develop a population pharmacokinetic model for doxorubicin and doxorubicinol that could provide improved estimated values for the pharmacokinetic parameters clearance of doxorubicin, volume of distribution of the central compartment, clearance of doxor...